Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinogen Medical ( (AU:ACW) ) has provided an update.
Actinogen Medical has amended the loan-funded long-term incentive arrangements for CEO Dr Steven Gourlay by extending the term of a secured, interest-free, limited recourse loan linked to his Loan Plan Shares by two years. The extension applies to an outstanding loan balance of about $1.93 million associated with shares issued in 2021 under the company’s employee share plan, which vest over three years subject to his continued employment.
The board noted that Gourlay has personally invested around $2.45 million in the company’s capital raisings, including a recent $500,000 subscription in a placement at $0.042 per share, and considers the loan extension to be reasonable remuneration. Directors argue the move is in shareholders’ best interests as it supports the CEO’s ongoing equity stake and encourages his participation in future capital raisings, thereby reinforcing leadership alignment with investor outcomes.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing Xanamem, a novel therapy targeting neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. The company’s lead programs centre on Alzheimer’s disease, alongside prior work in treatment-resistant depression, addressing substantial unmet medical need in cognitive and mood disorders.
YTD Price Performance: -39.34%
Average Trading Volume: 5,029,334
Technical Sentiment Signal: Sell
Current Market Cap: A$132.3M
For an in-depth examination of ACW stock, go to TipRanks’ Overview page.